121 related articles for article (PubMed ID: 21862729)
1. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
Wei J; Costa C; Ding Y; Zou Z; Yu L; Sanchez JJ; Qian X; Chen H; Gimenez-Capitan A; Meng F; Moran T; Benlloch S; Taron M; Rosell R; Liu B
J Natl Cancer Inst; 2011 Oct; 103(20):1552-6. PubMed ID: 21862729
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer.
Zheng WE; Chen H; Yuan SF; Wu LL; Zhang W; Sun HY; Chen WJ
J BUON; 2012; 17(2):284-90. PubMed ID: 22740207
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Wei J; Costa C; Shen J; Yu L; Sanchez JJ; Qian X; Sun X; Zou Z; Gimenez-Capitan A; Yue G; Guan W; Rosell R; Liu B
Br J Cancer; 2014 May; 110(11):2662-8. PubMed ID: 24809779
[TBL] [Abstract][Full Text] [Related]
4. Protein inhibitor of activated STAT-1 is downregulated in gastric cancer tissue and involved in cell metastasis.
Chen P; Zhao D; Sun Y; Huang L; Zhang S; Yuan Y
Oncol Rep; 2012 Dec; 28(6):2149-55. PubMed ID: 22972521
[TBL] [Abstract][Full Text] [Related]
5. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
Kim JW; Cho HJ; Kim M; Lee KH; Kim MA; Han SW; Oh DY; Lee HJ; Im SA; Kim TY; Yang HK; Kim WH; Bang YJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1435-43. PubMed ID: 23633032
[TBL] [Abstract][Full Text] [Related]
6. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Gao Y; Zhu J; Zhang X; Wu Q; Jiang S; Liu Y; Hu Z; Liu B; Chen X
PLoS One; 2013; 8(1):e52589. PubMed ID: 23326344
[TBL] [Abstract][Full Text] [Related]
9. Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Wei B; Han Q; Xu L; Zhang X; Zhu J; Wan L; Jin Y; Qian Z; Wu J; Gao Y; Zhou J; Chen X
BMC Cancer; 2015 Apr; 15():331. PubMed ID: 25925371
[TBL] [Abstract][Full Text] [Related]
10. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks.
Galanty Y; Belotserkovskaya R; Coates J; Polo S; Miller KM; Jackson SP
Nature; 2009 Dec; 462(7275):935-9. PubMed ID: 20016603
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
Dai GH; Shi Y; Chen L; Lv YL; Zhong M
Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
[TBL] [Abstract][Full Text] [Related]
12. Vimentin expression is associated with decreased survival in gastric cancer.
Otsuki S; Inokuchi M; Enjoji M; Ishikawa T; Takagi Y; Kato K; Yamada H; Kojima K; Sugihara K
Oncol Rep; 2011 May; 25(5):1235-42. PubMed ID: 21327330
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
15. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
[TBL] [Abstract][Full Text] [Related]
16. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma.
Yie SM; Yang H; Ye SR; Li K; Dong DD; Lin XM
Ann Surg Oncol; 2007 Oct; 14(10):2721-9. PubMed ID: 17564748
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
18. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis.
Sougioultzis S; Syrios J; Xynos ID; Bovaretos N; Kosmas C; Sarantonis J; Dokou A; Tzivras D; Zografos G; Felekouras E; Papalambros E; Tsavaris N
Eur J Surg Oncol; 2011 Apr; 37(4):312-8. PubMed ID: 21300519
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
Bamias A; Karina M; Papakostas P; Kostopoulos I; Bobos M; Vourli G; Samantas E; Christodoulou Ch; Pentheroudakis G; Pectasides D; Dimopoulos MA; Fountzilas G
Cancer Chemother Pharmacol; 2010 May; 65(6):1009-21. PubMed ID: 20130877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
